Publication date: Jul 01, 2026
Non-tuberculous mycobacterial pulmonary disease (NTM-PD) poses significant diagnostic challenges due to its clinical similarity to pulmonary tuberculosis (PTB). This study aimed to compare the clinical characteristics, immune status and lower respiratory tract microbiome profiles of NTM-PD and PTB patients. A total of 113 NTM-PD patients and 105 PTB patients were enrolled. The clinical features, laboratory parameters, and comorbidity profiles were analyzed. Bronchoalveolar lavage fluid (BALF) samples were subjected to bacterial culture and targeted next-generation sequencing (tNGS) for microbiome characterization. Microbiome distributions were then compared across disease groups, host characteristics, immune cell subsets, and NTM species. Compared with PTB patients, NTM-PD patients were older and exhibited lower rates of smoking, alcohol use, interferon-gamma release assay (IGRA) positivity, red blood cell (RBC) count, hemoglobin (Hb) and albumin levels, but a higher erythrocyte sedimentation rate (ESR). Hemoptysis, bronchiectasis, and chronic obstructive pulmonary disease (COPD) were more common among NTM-PD patients, while lymphadenopathy and diabetes were more frequent among PTB patients. BALF microbiome analysis revealed distinct profiles: Pseudomonas aeruginosa and Aspergillus spp. were more frequently detected in NTM-PD patients, while Neisseria spp. and Streptococcus viridans predominated in PTB patients. Reduced CD4⁺ T cell counts were associated with a higher detection rate of Pseudomonas aeruginosa and Candida spp. in NTM-PD patients. The most prevalent NTM species were the M. avium complex (MAC) (62. 37%) and the M. abscessus complex (MABC) (27. 96%). The lower respiratory tract microbiome in NTM-PD differs from that in PTB and is characterized by a high prevalence of Aspergillus spp. and Pseudomonas aeruginosa. These differences are likely influenced by underlying structural lung disease, host immune status, and the NTM species themselves. Our findings provide new insights for the precise diagnosis and treatment of NTM-PD.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Bacterial | Bronchoalveolar lavage fluid |
| Cd4 | Microbiome |
| Diabetes | Pulmonary tuberculosis |
| Host | Targeted next-generation sequencing |
| Lymphadenopathy |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | pulmonary disease |
| disease | MESH | pulmonary tuberculosis |
| pathway | REACTOME | Release |
| disease | MESH | Hemoptysis |
| disease | MESH | bronchiectasis |
| disease | MESH | chronic obstructive pulmonary disease |
| disease | MESH | lymphadenopathy |
| pathway | REACTOME | Reproduction |
| disease | MESH | included |
| disease | MESH | Tuberculosis |
| pathway | KEGG | Tuberculosis |
| disease | MESH | Emergency |
| disease | MESH | ext |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | infection |
| disease | MESH | respiratory diseases |
| disease | MESH | inflammation |
| disease | MESH | dysbiosis |
| disease | MESH | co infection |
| drug | DRUGBANK | P-nitrobiphenyl |
| drug | DRUGBANK | Prothrombin |
| disease | MESH | PCT |
| drug | DRUGBANK | Methyprylon |
| disease | MESH | autoimmune diseases |
| disease | MESH | HIV infection |
| pathway | REACTOME | HIV Infection |
| drug | DRUGBANK | Methionine |
| drug | DRUGBANK | Flunarizine |
| drug | DRUGBANK | Ethanol |